Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,763
archived clinical trials in
Colitis

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated:  11/9/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated: 11/9/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated:  11/9/2016
Clinical Research Facility
mi
from
Charlottesville, VA
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated: 11/9/2016
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated:  11/9/2016
Clinical Research Facility
mi
from
Chesapeake, VA
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated: 11/9/2016
Clinical Research Facility
mi
from
Chesapeake, VA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated:  11/9/2016
Clinical Research Facility
mi
from
Virginia Beach, VA
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated: 11/9/2016
Clinical Research Facility
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated:  11/9/2016
Clinical Research Facility
mi
from
Bellevue, WA
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated: 11/9/2016
Clinical Research Facility
mi
from
Bellevue, WA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated:  11/9/2016
Clinical Research Facility
mi
from
Seattle, WA
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated: 11/9/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated:  11/9/2016
Clinical Research Facility
mi
from
Madison, WI
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated: 11/9/2016
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated:  11/9/2016
Clinical Research Facility
mi
from
Madison, WI
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated: 11/9/2016
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated:  11/9/2016
Clinical Research Facility
mi
from
Jackson, MS
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated: 11/9/2016
Clinical Research Facility
mi
from
Jackson, MS
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated:  11/9/2016
mi
from
Urbana, MO
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated: 11/9/2016
mi
from
Urbana, MO
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated:  11/9/2016
mi
from
Adelaide,
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
Status: Enrolling
Updated: 11/9/2016
mi
from
Adelaide,
Click here to add this to my saved trials
Extended Treatment With Vancomycin for Clostridium Difficile Colitis
Comparative Study of 2 Weeks Versus 4 Weeks Treatment With Vancomycin for Clostridium Difficile Colitis
Status: Enrolling
Updated:  12/13/2016
William Beaumont Hospital
mi
from
Royal Oak, MI
Extended Treatment With Vancomycin for Clostridium Difficile Colitis
Comparative Study of 2 Weeks Versus 4 Weeks Treatment With Vancomycin for Clostridium Difficile Colitis
Status: Enrolling
Updated: 12/13/2016
William Beaumont Hospital
mi
from
Royal Oak, MI
Click here to add this to my saved trials
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
National City, CA
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
National City, CA
Click here to add this to my saved trials
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Denver, CO
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Golden, CO
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Golden, CO
Click here to add this to my saved trials
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Maitland, FL
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Maitland, FL
Click here to add this to my saved trials
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Winter Park, FL
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Winter Park, FL
Click here to add this to my saved trials
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Zephyrhills, FL
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Zephyrhills, FL
Click here to add this to my saved trials
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Suwanee, GA
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Suwanee, GA
Click here to add this to my saved trials
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Idaho Falls, ID
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Rochester, MN
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Kansas City, MO
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Columbia, SC
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Chesapeake, VA
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Chesapeake, VA
Click here to add this to my saved trials
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
La Jolla, CA
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Crestview Hills, KY
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Crestview Hills, KY
Click here to add this to my saved trials
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/4/2017
Clinical Research Facility
mi
from
Cincinnati, OH
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/4/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated:  1/4/2017
mi
from
Gent,
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Status: Enrolling
Updated: 1/4/2017
mi
from
Gent,
Click here to add this to my saved trials
Lactobacillus GG in Pediatric Ulcerative Colitis (UC)
An Open Label Pilot Study of Lactobacillus GG in Pediatric Ulcerative Colitis
Status: Enrolling
Updated:  2/6/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Lactobacillus GG in Pediatric Ulcerative Colitis (UC)
An Open Label Pilot Study of Lactobacillus GG in Pediatric Ulcerative Colitis
Status: Enrolling
Updated: 2/6/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  3/14/2017
The University of California, San Diego
mi
from
La Jolla, CA
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 3/14/2017
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  3/14/2017
Atlanta Gastroenterology Associates
mi
from
Atlanta, GA
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 3/14/2017
Atlanta Gastroenterology Associates
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  3/14/2017
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 3/14/2017
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  3/14/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 3/14/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  3/14/2017
Long Island Clin Rsch Asc, LLP
mi
from
Great Neck, NY
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 3/14/2017
Long Island Clin Rsch Asc, LLP
mi
from
Great Neck, NY
Click here to add this to my saved trials
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  3/14/2017
Consultants for Clin. Rsrch
mi
from
Cincinnati, OH
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 3/14/2017
Consultants for Clin. Rsrch
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Placental Transfusion Project for Preterm Infants
Placental Transfusion in Preterm Infants Born at Less Than 34 Weeks of Gestation … Role of "Delayed" Cord Clamping and Umbilical Cord Milking
Status: Enrolling
Updated:  3/15/2017
Riley Hospital for Children
mi
from
Indianapolis, IN
Placental Transfusion Project for Preterm Infants
Placental Transfusion in Preterm Infants Born at Less Than 34 Weeks of Gestation … Role of "Delayed" Cord Clamping and Umbilical Cord Milking
Status: Enrolling
Updated: 3/15/2017
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Effects of L-Arginine in Colitis and Colon Cancer
Immunomodulary Effects of Arginine Supplementation in Colitis and Colon Cancer
Status: Enrolling
Updated:  3/30/2017
Vanderbilt Hospital
mi
from
Nashville, TN
Study of Effects of L-Arginine in Colitis and Colon Cancer
Immunomodulary Effects of Arginine Supplementation in Colitis and Colon Cancer
Status: Enrolling
Updated: 3/30/2017
Vanderbilt Hospital
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Freeze-dried Black Raspberry in Maintenance of Ulcerative Colitis
A Trial of Freeze-dried Black Raspberry in Maintenance of Remission of Ulcerative Colitis
Status: Enrolling
Updated:  4/10/2017
University of Connecticut Health Center
mi
from
Farmington, CT
Study of Freeze-dried Black Raspberry in Maintenance of Ulcerative Colitis
A Trial of Freeze-dried Black Raspberry in Maintenance of Remission of Ulcerative Colitis
Status: Enrolling
Updated: 4/10/2017
University of Connecticut Health Center
mi
from
Farmington, CT
Click here to add this to my saved trials
Study of Freeze-dried Black Raspberry in Maintenance of Ulcerative Colitis
A Trial of Freeze-dried Black Raspberry in Maintenance of Remission of Ulcerative Colitis
Status: Enrolling
Updated:  4/10/2017
University of Connecticut Health Center
mi
from
Farmington, CT
Study of Freeze-dried Black Raspberry in Maintenance of Ulcerative Colitis
A Trial of Freeze-dried Black Raspberry in Maintenance of Remission of Ulcerative Colitis
Status: Enrolling
Updated: 4/10/2017
University of Connecticut Health Center
mi
from
Farmington, CT
Click here to add this to my saved trials
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated:  4/24/2017
University of Southern California
mi
from
Los Angeles, CA
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated: 4/24/2017
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated:  4/24/2017
University of Colorado
mi
from
Denver, CO
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated: 4/24/2017
University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated:  4/24/2017
Atlanta Gastroenterology
mi
from
Atlanta, GA
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated: 4/24/2017
Atlanta Gastroenterology
mi
from
Atlanta, GA
Click here to add this to my saved trials
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated:  4/24/2017
Northwestern University
mi
from
Chicago, IL
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated: 4/24/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated:  4/24/2017
University of Chicago
mi
from
Chicago, IL
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated: 4/24/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated:  4/24/2017
Indiana University IU Health
mi
from
Indianapolis, IN
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated: 4/24/2017
Indiana University IU Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated:  4/24/2017
University of Iowa
mi
from
Iowa City, IA
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated: 4/24/2017
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated:  4/24/2017
University of Kentucky
mi
from
Lexington, KY
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated: 4/24/2017
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated:  4/24/2017
University of Louisville
mi
from
Louisville, KY
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated: 4/24/2017
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated:  4/24/2017
University of Maryland
mi
from
Baltimore, MD
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated: 4/24/2017
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated:  4/24/2017
Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)
Status: Enrolling
Updated: 4/24/2017
Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Click here to add this to my saved trials